Effects of the histone deacetylase inhibitor valproic acid on human pericytes In Vitro

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Karén, Jakob ^a   Rodriguez, Alejandro ^a   Friman, Tomas ^a   Dencker, Lennart ^a   Sundberg, Christian ^a,b   Scholz, Birger ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 ET 4 ME PENTA; COLLAGEN TYPE 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; DRUG EXPOSURE; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PERICYTE; PHENOTYPE; POLYMERASE CHAIN REACTION; CELL MOTION; CELL SURVIVAL; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; MICROCIRCULATION; PLACENTA; PREGNANCY;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PERICYTES; PHENOTYPE; PLACENTA; POLYMERASE CHAIN REACTION; PREGNANCY; VALPROIC ACID;

EID: 80053066716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024954     Document Type: Article

References (77)

1. Rhodin JAG, (1968) Ultrastructure of mammalian venous capillaries, venules, and small collecting veins. J Ultrastruct Res 25: 452-500.
2. Yamagishi S, Imaizumi T, (2005) Pericyte biology and diseases. Int J Tissue React 27: 125-135.
3. Sevigny J, Sundberg C, Braun N, Guckelberger O, Csizmadia E, et al. (2002) Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation. Blood 99: 2801-2809.
4. Díaz-Flores L, Gutierrez R, Gonzalez P, Varela H, (1991) Inducible perivascular cells contribute to the neochondrogenesis in grafted perichondrium. Anat Rec 229: 1-8.
5. Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, et al. (2004) Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 110: 2226-2232.
6. Ivarsson M, Sundberg C, Farrokhnia N, Pertoft H, Rubin K, et al. (1996) Recruitment of type I collagen producing cells from the microvasculature in vitro. Exp Cell Res 229: 336-349.
7. Sundberg C, Ivarsson M, Gerdin B, Rubin K, (1996) Pericytes as collagen producing cells in excessive dermal scarring. Lab Invest 74: 452-466.
8. Sundberg C, Kowanetz M, Brown LF, Detmar M, Dvorak HF, (2002) Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82: 387-401.
9. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K, (1993) Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 143: 1377-1388.
10. Rodriguez A, Karen J, Gardner H, Gerdin B, Rubin K, et al. (2009) Integrin α1β1 is Involved in the Differentiation into Myofibroblasts in Adult Reactive Tissues in vivo. J Cell Mol Med 13: 3449-3462.
11. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM, (1999) Activation of microvascular pericytes in autoimmune Raynaud's and systemic sclerosis. Arthritis & Rheum 42: 930-941.
12. Lin SL, Kisseleva T, Brenner DA, Duffield JS, (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173: 1617-1627.
13. Fuchs D, Rodriguez A, Eriksson S, Christofferson R, Sundberg C, et al. (2010) Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int J Cancer 126: 2773-2789.
14. Karberg S, (2009) Switching on epigenetic therapy. Cell 139: 1029-1031.
15. Surani MA, Hayashi K, Hajkova P, (2007) Genetic and epigenetic regulators of pluripotency. Cell 128: 747-762.
16. Surani MA, Durcova-Hills G, Hajkova P, Hayashi K, Tee WW, (2008) Germ line, stem cells, and epigenetic reprogramming. Cold Spring Harb Symp Quant Biol 73: 9-15.
17. Yang XJ, Seto E, (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26: 5310-5318.
18. Marks PA, Richon VM, Rifkind RA, (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
19. Marks PA, Richon VM, Miller T, Kelly WK, (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168.
20. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
21. Eikel D, Hoffmann K, Zoll K, Lampen A, Nau H, (2006) S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides. Drug Metab Dispos 34: 612-620.
22. Eikel D, Lampen A, Nau H, (2006) Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19: 272-278.
23. Dichter MA, Brodie MJ, (1996) New antiepileptic drugs. N Engl J Med 334: 1583-1590.
24. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, et al. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
25. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
26. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, et al. (2007) Modulationof angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151: 63-72.
27. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R, et al. (2007) Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67: 1099-1110.
28. Gao D, Xia Q, Lv J, Zhang H, (2007) Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Int J Urol 14: 838-845.
29. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, et al. (2006) Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ 13: 446-453.
30. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, et al. (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112: 863-871.
31. Chung YL, Wang AJ, Yao LF, (2004) Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 3: 317-325.
32. Mannaerts I, Nuytten NR, Rogiers V, Vanderkerken K, van Grunsven LA, et al. (2010) Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatology 51: 603-614.
33. Jergil M, Forsberg M, Salter H, Stockling K, Gustafson AL, et al. (2011) Short-time gene expression response to valproic Acid and valproic Acid analogs in mouse embryonic stem cells. Toxicol Sci 121: 328-342.
34. Eickholt BJ, Towers GJ, Ryves WJ, Eikel D, Adley K, et al. (2005) Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3β inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol Pharmacol 67: 1426-1433.
35. Riebeling C, Pirow R, Becker K, Buesen R, Eikel D, et al. (2011) The embryonic stem cell test as tool to assess structure-dependent teratogenicity: the case of valproic acid. Toxicol Sci 120: 360-370.
36. Lyons AB, Parish CR, (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171: 131-137.
37. Soderholm J, Heald R, (2005) Scratch n' screen for inhibitors of cell migration. Chem Biol 12: 263-265.
38. Schlingemann RO, Rietveld FJR, de Waal RMW, Ferrone S, Ruiter DJ, (1990) Expression of the high molecular weight-melanoma associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Path 136: 1393-1405.
39. Schlingemann RO, Rietveld FJR, Kwaspen F, van der Kerkhof FPC, de waal MW, et al. (1991) Differential expression of markers for endothelial cells, pericytes and basal lamina in the microvasculature of tumors and granulation tissue. Am J Path 138: 1335-1347.
40. Skalli O, Ropraz P, Trzeciak A, Benzonona G, Gilessen D, et al. (1986) A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103: 2787-2796.
41. Plouffe BD, Kniazeva T, Mayer JE Jr, Murthy SK, Sales VL, (2009) Development of microfluidics as endothelial progenitor cell capture technology for cardiovascular tissue engineering and diagnostic medicine. FASEB J 23: 3309-3314.
42. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, et al. (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313.
43. Singer KH, Searce RM, Tuck DT, Wichard LP, Denning SM, et al. (1989) Removal of fibroblasts from human epithelial cell cultures with use of a complement fixing monoclonal antibody reactive with human fibroblasts and monocytes/macrophages. J Invest Dermatol 92: 166-170.
44. Lyons AB, (1999) Divided we stand: tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester. Immunol Cell Biol 77: 509-515.
45. Jain RK, (2003) Molecular regulation of vessel maturation. Nat Med 9: 685-693.
46. Benjamin L, Golijanin D, Itin A, Pode D, Keshet E, (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165.
47. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27-31.
48. Hantash BM, Zhao L, Knowles JA, Lorenz HP, (2008) Adult and fetal wound healing. Front Biosci 13: 51-61.
49. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, et al. (2006) Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A 103: 18721-18726.
50. Cazes A, Galaup A, Chomel C, Bignon M, Brechot N, et al. (2006) Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 99: 1207-1215.
51. Li A, Dubey S, Varney ML, Dave BJ, Singh RK, (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376.
52. Li A, Dubey S, Varney ML, Singh RK, (2002) Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells. Microvasc Res 64: 476-481.
53. Suhardja A, Hoffman H, (2003) Role of growth factors and their receptors in proliferation of microvascular endothelial cells. Microsc Res Tech 60: 70-75.
54. Garfinkel S, Hu X, Prudovsky IA, McMahon GA, Kapnik EM, et al. (1996) FGF-1-dependent proliferative and migratory responses are impaired in senescent human umbilical vein endothelial cells and correlate with the inability to signal tyrosine phosphorylation of fibroblast growth factor receptor-1 substrates. J Cell Biol 134: 783-791.
55. Weinstein M, Xu X, Ohyama K, Deng CX, (1998) FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 125: 3615-3623.
56. Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE, (2008) Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28: 1703-1713.
57. Davis GE, Senger DR, (2005) Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97: 1093-1107.
58. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, et al. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74.
59. Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE, (2009) Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 114: 5091-5101.
60. Hallmann R, Horn N, Selg M, Wendler O, Pausch F, et al. (2005) Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 85: 979-1000.
61. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, et al. (2006) Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 175: 179-191.
62. Monnier J, Samson M, (2010) Prokineticins in angiogenesis and cancer. Cancer Lett 296: 144-149.
63. Guilini C, Urayama K, Turkeri G, Dedeoglu DB, Kurose H, et al. (2010) Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration. Am J Physiol Heart Circ Physiol 298: H844-852.
64. Kzhyshkowska J, Gratchev A, Goerdt S, (2006) Stabilin-1, a homeostatic scavenger receptor with multiple functions. J Cell Mol Med 10: 635-649.
65. Le Y, Zhou Y, Iribarren P, Wang J, (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1: 95-104.
66. Keane MP, Arenberg DA, Moore BB, Addison CL, Strieter RM, (1998) CXC chemokines and angiogenesis/angiostasis. Proc Assoc Am Physicians 110: 288-296.
67. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissel MJ, (1995) The origin of myofibroblasts in breast cancer. J Clin Invest 95: 859-873.
68. Crosby JR, Tappan KA, Seifert RA, Bowen-Pope DF, (1999) Chimeric analysis reveals that fibroblasts and endothelial cells require platelet-derived growth factor receptor β expression for participation in reactive connective tissue formation in adults but not during development. Am J Pathol 154: 1315-1321.
69. Forsberg K, Valji-Nagi L, Heldin C-H, Herlyn M, Westermark B, (1993) Platelet-derived growth factor(PDGF): Developement of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90: 393-397.
70. Pierce GF, Berg JV, Rudolph R, Tarpley J, Mustoe TA, (1991) Platlet-derived growth factor-BB and transforming growth factor β1 selectively modulate glycoaminoglycans, collagen and myofibroblasts in excisional wounds. Am J Path 145: 629-646.
71. Rombouts K, Niki T, Wielant A, Hellemans K, Geerts A, (2001) Trichostatin A, lead compound for development of antifibrogenic drugs. Acta Gastroenterol Belg 64: 239-246.
72. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, et al. (2002) Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGFβ(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 278: 184-197.
73. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA, (2009) Abrogation of TGFβ1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 297: L864-870.
74. Freidkin I, Herman M, Tobar A, Chagnac A, Ori Y, et al. (2010) Effects of histone deacetylase inhibitors on rat mesangial cells. Am J Physiol Renal Physiol 298: F426-434.
75. Bulow R, Fitzner B, Sparmann G, Emmrich J, Liebe S, et al. (2007) Antifibrogenic effects of histone deacetylase inhibitors on pancreatic stellate cells. Biochem Pharmacol 74: 1747-1757.
76. Lindahl P, Hellstrom M, Kalen M, Betsholtz C, (1998) Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. Curr Opin Lipidol 9: 407-411.
77. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, et al. (2007) Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A 104: 3996-4001.